CA2676609A1 - Methods and compositions for treating neuropathies - Google Patents

Methods and compositions for treating neuropathies

Info

Publication number
CA2676609A1
CA2676609A1 CA 2676609 CA2676609A CA2676609A1 CA 2676609 A1 CA2676609 A1 CA 2676609A1 CA 2676609 CA2676609 CA 2676609 CA 2676609 A CA2676609 A CA 2676609A CA 2676609 A1 CA2676609 A1 CA 2676609A1
Authority
CA
Grant status
Application
Patent type
Prior art keywords
nad
activity
ampk
cells
neurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2676609
Other languages
English (en)
French (fr)
Inventor
Jeffrey Milbrandt
Biplab Dasgupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis
Original Assignee
Washington University
Jeffrey Milbrandt
Biplab Dasgupta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
CA 2676609 2007-01-26 2008-01-28 Methods and compositions for treating neuropathies Abandoned CA2676609A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US88685407 true 2007-01-26 2007-01-26
US60/886,854 2007-01-26
PCT/US2008/001085 WO2008091710A3 (en) 2007-01-26 2008-01-28 Methods and compositions for treating neuropathies

Publications (1)

Publication Number Publication Date
CA2676609A1 true true CA2676609A1 (en) 2008-07-31

Family

ID=39645095

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2676609 Abandoned CA2676609A1 (en) 2007-01-26 2008-01-28 Methods and compositions for treating neuropathies

Country Status (4)

Country Link
US (3) US20100047177A1 (3Den)
EP (1) EP2124985A4 (3Den)
CA (1) CA2676609A1 (3Den)
WO (1) WO2008091710A3 (3Den)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2259782A4 (en) 2008-03-03 2013-01-23 Nad Life Pty Ltd Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
EP2323649A4 (en) * 2008-07-25 2011-09-07 Univ Emory Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
WO2010077642A1 (en) 2008-12-08 2010-07-08 Northwestern University Method of modulating hsf-1
JP2010215563A (ja) * 2009-03-17 2010-09-30 Kao Corp Lkb1活性化剤
WO2011156479A9 (en) 2010-06-09 2012-05-31 Emory University Trkb agonists and methods of use
CN102305863B (zh) * 2011-07-18 2013-11-20 厦门大学 以Nur77-LKB1相互作用为靶点的抗糖尿病药物筛选方法
US9593125B2 (en) 2012-07-27 2017-03-14 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
EP2968306A4 (en) 2013-03-15 2016-11-02 Univ Washington Administration of nicotinamide mononucleotide in the treatment of disease
CN103877076B (zh) * 2014-03-21 2016-06-29 景临林 5,6,7,8-四羟基黄酮在制备抗缺氧药物中的应用
CN106715455A (zh) 2014-06-06 2017-05-24 葛兰素史密斯克莱知识产权(第2 号)有限公司 烟酰胺核苷类似物及其药物组合物和用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512789A (ja) * 1998-04-28 2002-05-08 マイトコー 変化したミトコンドリア機能に関連する疾患の細胞および動物モデル
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
WO2000021526A1 (en) * 1998-10-09 2000-04-20 Sigma-Tau Healthscience S.P.A. Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders
CA2374612A1 (en) * 1999-05-28 2000-12-07 Immunex Corporation Novel murine and human kinases
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
WO2004021980B1 (en) * 2002-09-09 2004-08-19 Mitochroma Res Inc Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation
GB2402938B (en) * 2003-06-17 2005-11-09 Medical Res Council Kinase assay
US20050096256A1 (en) * 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20070105109A1 (en) * 2003-07-02 2007-05-10 Geesaman Bard J Sirt1 and genetic disorders
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2007527418A (ja) * 2003-12-29 2007-09-27 ザ ジェネラル ホスピタル コーポレーション 肥満及びインシュリン耐性障害を治療又は防止するための組成物
EP1723227A4 (en) * 2004-02-10 2007-09-19 Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
US20050227327A1 (en) * 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
EP3006040B1 (en) * 2004-06-04 2017-11-22 Washington University Methods and compositions for treating neuropathies
US20060035302A1 (en) * 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
WO2006001278A1 (ja) * 2004-06-28 2006-01-05 Kao Corporation Ampk活性化剤
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
CN103055313A (zh) * 2005-07-07 2013-04-24 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
WO2007019416A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
KR101460820B1 (ko) * 2007-01-16 2014-11-11 아이피아이엔티엘, 엘엘씨 대사 증후군의 치료를 위한 신규한 조성물

Also Published As

Publication number Publication date Type
US20160367497A1 (en) 2016-12-22 application
US20100047177A1 (en) 2010-02-25 application
WO2008091710A2 (en) 2008-07-31 application
EP2124985A2 (en) 2009-12-02 application
EP2124985A4 (en) 2011-06-08 application
WO2008091710A3 (en) 2008-10-09 application
US20140011890A1 (en) 2014-01-09 application

Similar Documents

Publication Publication Date Title
Brami-Cherrier et al. Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation
Albani et al. The SIRT1 activator resveratrol protects SK‐N‐BE cells from oxidative stress and against toxicity caused by α‐synuclein or amyloid‐β (1‐42) peptide
David et al. Parthanatos, a messenger of death
Papouin et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists
Kotecha et al. A Kv1. 5 to Kv1. 3 switch in endogenous hippocampal microglia and a role in proliferation
Wong et al. Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling
Wood-Kaczmar et al. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons
Vives-Bauza et al. Mitophagy: the latest problem for Parkinson's disease
Langley et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21waf1/cip1 in cell cycle-independent neuroprotection
Bhattacharjee et al. Localization of the Slack potassium channel in the rat central nervous system
Morfini et al. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport
Rakovic et al. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients
Pilsl et al. Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson’s disease
US20060276393A1 (en) Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
Sasaki et al. Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide
Peña et al. Stress-induced apoptosis and the sphingomyelin pathway
Thorens GLUT2, glucose sensing and glucose homeostasis
Liesa et al. Mitochondrial dynamics in mammalian health and disease
Simon et al. A caspase cascade regulating developmental axon degeneration
Franke et al. Pathophysiology of astroglial purinergic signalling
Pilgram et al. The roles of the dystrophin-associated glycoprotein complex at the synapse
Boison Adenosine kinase: exploitation for therapeutic gain
Morfini et al. Fast axonal transport misregulation and Alzheimer’s disease
Boison Adenosine dysfunction in epilepsy
Nazıroğlu TRPM2 cation channels, oxidative stress and neurological diseases: where are we now?

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130128

FZDE Dead

Effective date: 20170804